BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38236528)

  • 1. Urine Mast Cell Mediators in the Evaluation and Diagnosis of Mast Cell Activation Syndrome.
    Voelker D; Pongdee T
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):33-38. PubMed ID: 38236528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
    Butterfield JH
    Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1974-1984. PubMed ID: 35346887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
    Butterfield JH; Ravi A; Pongdee T
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
    Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
    Butterfield JH; Weiler CR
    Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
    Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Rubin P; Cohn J; White MV; Igarashi Y; Kaliner MA; Drazen JM
    J Allergy Clin Immunol; 1994 Dec; 94(6 Pt 1):1046-56. PubMed ID: 7798537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis.
    Ono E; Taniguchi M; Mita H; Fukutomi Y; Higashi N; Miyazaki E; Kumamoto T; Akiyama K
    Clin Exp Allergy; 2009 Jan; 39(1):72-80. PubMed ID: 19128354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the role of PGD2 metabolites as markers of mast cell activation in asthma.
    O'Sullivan S
    Acta Physiol Scand Suppl; 1999 Apr; 644():1-74. PubMed ID: 10352758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma.
    Mita H; Endoh S; Kudoh M; Kawagishi Y; Kobayashi M; Taniguchi M; Akiyama K
    Allergy; 2001 Nov; 56(11):1061-7. PubMed ID: 11703219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cell activation syndrome: a review.
    Frieri M; Patel R; Celestin J
    Curr Allergy Asthma Rep; 2013 Feb; 13(1):27-32. PubMed ID: 23179866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia.
    Giannetti MP; Godwin G; Weller E; Butterfield JH; Castells M
    J Allergy Clin Immunol; 2022 Nov; 150(5):1225-1227. PubMed ID: 35550148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of mast cell activation and leukotriene release after mannitol inhalation.
    Brannan JD; Gulliksson M; Anderson SD; Chew N; Kumlin M
    Eur Respir J; 2003 Sep; 22(3):491-6. PubMed ID: 14516140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma.
    Bochenek G; Nizankowska E; Gielicz A; Swierczyńska M; Szczeklik A
    Thorax; 2004 Jun; 59(6):459-64. PubMed ID: 15170023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
    Castells M; Butterfield J
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
    Cahill KN; Wu P; Milne GL; Amin T; Singer J; Murphy K; Lewis E; Gapko D; Boyce JA; Buchheit KM; Laidlaw TM
    J Allergy Clin Immunol; 2022 Jul; 150(1):170-177.e6. PubMed ID: 35026207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
    Divekar R; Butterfield J
    Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.